Unokavi (Phytomenadione/Vitamin K₁) is a therapeutic agent that is primarily applied for the supportive management of impaired blood coagulation, focusing on conditions that lead to a high risk of uncontrolled bleeding. The core therapeutic benefit supports the re-establishment of the body’s ability to form essential blood clots when that function is compromised.

The medication is utilized for the management of various coagulation disorders due to faulty formation of clotting factors when caused by Vitamin K deficiency or interference with its activity, and for the prophylaxis and treatment of Vitamin K-deficiency bleeding in neonates.

Urgent Reversal of Excessive Blood Thinning

This domain is applicable within clinical settings that involve acute or unstable symptom patterns related to excessive blood thinning caused by coumarin-type anticoagulants. Unokavi is commonly used to address this drug-induced state, assists in managing, and may contribute to the prevention of active hemorrhage or the critical risk associated with dangerously high International Normalized Ratio (INR) levels.

Correction of Deficiency-Related Bleeding Tendencies

Unokavi is applied across domains where additional symptomatic support is needed for hypoprothrombinemia and other symptoms of acquired Vitamin K deficiency. This is relevant in conditions where functional stability may become affected by poor absorption, such as malabsorption syndromes. By addressing these symptoms related to systemic imbalance, the treatment helps reduce the overall burden of persistent bleeding risk.

Quick Fact: Relief for Bleeding Risk
Primary Use Context	Acute reversal of excessive anticoagulation in emergency settings.
Symptom Managed	Dangerously high INR levels and active hemorrhage manifestations.
Patient Benefit	Supports the re-establishment of safe clotting function.

Regulatory References

1. NIH StatPearls Overview

Eligibility Scope for Unokavi

Official regulatory documents define eligibility based on specific population categories, age groups, and certain pre-existing conditions.

Category	Official Regulatory Status
Populations Contraindicated	Patients with a known hypersensitivity to the active ingredient (Phytonadione) or any other component of the specific formulation.
Populations Allowed	Adults are approved for labeled indications. Neonates and Infants are an approved population for the prophylaxis and treatment of Vitamin K-Deficiency Bleeding.
Age-Related Restrictions	The safety and effectiveness of the oral and injectable forms have not been established in pediatric patients from 6 months to 17 years. Data for older adults are insufficient to confirm differential responses.
Formulation Restrictions	Injectable formulations containing the benzyl alcohol preservative are not recommended for use in neonates and infants due to the risk of serious adverse reactions, including “Gasping Syndrome.”
Conditional Use	Pregnancy and Lactation are assigned a Category C, and use is contingent on the clinical need justifying the potential risk; preservative-free formulations are recommended.
Comorbidity Limitation	For patients with severe liver dysfunction, repeated large doses are officially not warranted if there is no satisfactory response to the initial dose.

These official statements structure who can and cannot use the medicine, ranging from absolute prohibitions to conditional use based on age, physiological status, and the specific formulation's components.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Unokavi (Phytomenadione/Vitamin K₁) based on its core physiological role as an antihemorrhagic agent. The primary clinical interactions are characterized by effects on other blood-clotting agents and substances that affect the medicine's absorption.

Pharmacodynamic and Antagonistic Interactions

Interaction Type	Interacting Substances	Official Regulatory Outcome
Antagonism	Prothrombin-Depressing Anticoagulants (e.g., Warfarin)	May induce temporary resistance to the anticoagulant effect, potentially requiring an increase in the anticoagulant dose if therapy is resumed.
Absence of Interaction	Heparin	Unokavi does not counteract the anticoagulant action of Heparin.
Interference	Salicylates and certain Antibiotics	Unokavi is documented for correcting hypoprothrombinemia caused by these substances' interference with Vitamin K metabolism.

Pharmacokinetic and Absorption Constraints

Oral Unokavi exposure may be significantly reduced when co-administered with substances that interfere with the absorption of fat-soluble vitamins. Mineral Oil and the anti-obesity agent Orlistat are documented to decrease the systemic levels of oral Phytomenadione by inhibiting its gastrointestinal uptake. For the oral dosage form, a practical constraint is noted: absorption requires the presence of bile salts, necessitating co-administration when the endogenous supply is deficient.

The active ingredient, Phytomenadione (Vitamin K1), operates by driving the intrinsic mechanism of blood coagulation, functioning as a critical co-factor within the liver.

Key Enzyme Targets and Co-Factor Cycling

Unokavi initiates its effect by acting as a substrate for Vitamin K Epoxide Reductase (VKOR), which converts it into the necessary active form, Vitamin K Hydroquinone ( KH2). This KH2 then serves as the essential co-factor for the enzyme gamma-Glutamyl Carboxylase (GGCX). This cycling mechanism facilitates the continuous availability of the component required to drive the subsequent activation of key coagulation proteins.

Protein Activation and Systemic Hemostasis

The KH2 co-factor enables GGCX to perform a vital post-translational modification known as gamma-carboxylation, which chemically alters inactive coagulation factors (like Factor II, VII, IX, and X). This modification creates Gla-residues, specialized binding sites that grant the factors the ability to anchor firmly to surfaces via calcium ions ( Ca^2+). By enabling the synthesis and secretion of these fully functional proteins, the mechanism restores the efficiency of the coagulation cascade, directly re-establishing the systemic capacity for blood clot formation. The time required for the liver to de novo synthesize and release these activated factors imposes an inherent constraint on the onset of the physiological effect.

Unokavi (Phytomenadione) is administered according to the urgency of the clinical scenario, utilizing its two primary forms: the oral tablet and the injectable emulsion. The medicine is administered via the oral route for the tablet form, and the injectable form permits subcutaneous (SC), intravenous (IV), and intramuscular (IM) administration. For non-emergency parenteral use, the subcutaneous route is generally preferred. The intravenous route is reserved for acute, severe conditions where rapid action is required and must be delivered very slowly, with the infusion rate not exceeding 1 mg per minute.

Standard adult dosing for non-acute reversal of excessive anticoagulation typically involves an initial dose of 2.5 mg to 10 mg. In cases of severe hemorrhage, an initial IV dose usually falls between 5 mg and 10 mg. Dosing is generally initiated as a single application, with the need for repeat dosing determined by the patient's prothrombin time response, monitored by the International Normalized Ratio (INR). Repeat parenteral doses may be administered after 6 to 8 hours if the initial response is insufficient. For neonates, a specific prophylactic regimen is established, often involving a single dose of 0.5 mg to 1 mg via the intramuscular or subcutaneous route. Preparation of the injectable emulsion requires dilution only with specified solutions (e.g., 0.9% sodium chloride) and must be used immediately after preparation.

Unokavi: Recent Clinical Evidence

Research into Unokavi, a selective inhibitor of the PDE4 enzyme, has focused on its potential role in managing moderate-to-severe plaque psoriasis. The drug's evaluation centers on its effect on the inflammatory processes associated with the condition.

Efficacy and Key Trial Outcomes

Phase 3 randomized controlled trials (RCTs) investigated the drug's effect on key clinical measures, including the Psoriasis Area and Severity Index (PASI) score. Data from these studies indicated that a proportion of adult participants achieved an outcome of a 75% reduction in PASI (PASI-75) by the 16-week mark when compared to a placebo group. Further studies have evaluated the drug's potential to affect mild-to-moderate forms of the condition, as well as its effect on the participants' overall quality of life (QoL).

Outcome Measure	Study Finding (Example)
PASI-75 Response	Achieved by a percentage of participants at Week 16 vs. placebo.
QoL	Studies examined its effect on the Psoriasis Symptom Diary (PSSD) and DLQI scores.

Adverse Event Profile

The adverse event profile was examined in adult participants across the clinical studies. Adverse events documented in participants commonly included gastrointestinal events (such as nausea and diarrhea) and headache. Discontinuation from the studies due to adverse events was reported in a small percentage of participants.

Specific populations, such as participants with severe liver impairment, were not included in the primary trials. Clinical research protocols often included the monitoring of participants for weight change and mood-related changes throughout the study periods.

Key Studies & References

1. A Phase 3, Randomized, Multicenter, Double-Blind, Placebo- and Active Comparator-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of [Drug Placeholder] in Subjects With Moderate-to-Severe Plaque Psoriasis (NCT0XXXXXXX)
2. Treatment goals for psoriasis: Should PASI 90 become the standard of care?

Common questions about Unokavi (FAQ)

Q: What is the brand name of Phytomenadione?

The active ingredient in this medicine is Phytomenadione, which is also known as Phytonadione or Vitamin K₁. Unokavi is one of the proprietary, or brand, names used for this active ingredient. You may see the same substance marketed under other brand names as well, such as AquaMEPHYTON or Mephyton, according to official information.

Q: How long does it takes for Unokavi to start working?

According to official regulatory documents, when the injectable form of Unokavi is given intravenously, its action can typically be detected within one to three hours. The bleeding is generally reported to be controlled within three to six hours. Regulatory documents indicate that the time to achieve a normal prothrombin level, which measures clotting ability, is reported to be approximately 12 to 14 hours in clinical data.

Q: What is the typical adult dose of Unokavi for acute severe bleeding?

Official prescribing information indicates that the dose used for severe or life-threatening bleeding related to anticoagulant therapy is administered intravenously and falls within a specific range. Dosing must always be determined by a healthcare professional based on the specific clinical needs of the patient. Decisions regarding the need for repeat dosing and adjustments are clinically based and guided by monitoring the patient's prothrombin time response.

Q: What are the most common side effects of Unokavi?

Studies and official information indicate that commonly reported effects are often transient (temporary). These can include a peculiar sensation of taste and a feeling of flushing or warmth. Adverse event profiles also indicate that gastrointestinal effects, such as nausea and diarrhea, as well as headache, have been reported in clinical studies.

Q: Can children and teens use Unokavi?

Official documents confirm that Unokavi is approved for use in neonates and infants to prevent and treat bleeding caused by Vitamin K deficiency. For pediatric patients between 6 months and 17 years of age, official information notes that the safety and effectiveness of the oral and injectable forms have not yet been established.

Unokavi (Phytomenadione) must be stored and handled according to specific regulatory requirements to maintain its stability and ensure environmental safety.

Official Storage Conditions

• Temperature: Store the injectable emulsion at Controlled Room Temperature (20 C to 25 C), with permissible excursions up to 30 C. The product must not be frozen.
• Light Protection: The medicine is sensitive to light; ampules must be protected from light at all times and should be kept in the original carton until the time of use.
• Stability: If the product is diluted for administration, it must be used immediately after dilution. Any unused portion of the diluted solution or the ampule contents must be discarded.
• Child Safety: Keep Unokavi out of the sight and reach of children.

Disposal

Discard all unused or expired medication according to local pharmaceutical waste regulations. Needles or syringes must be immediately placed in an approved sharps disposal container. Official guidelines recommend utilizing drug take-back programs and avoiding disposal into household trash or down the sink.